MEDIROM HEALTHCARE TECHNOLOG (MRM) Fundamental Analysis & Valuation

NASDAQ:MRM • US58510H1032

1.3 USD
0 (0%)
At close: Mar 9, 2026
1.26 USD
-0.04 (-3.08%)
Pre-Market: 3/10/2026, 6:08:34 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MRM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to MRM. MRM was compared to 74 industry peers in the Diversified Consumer Services industry. MRM may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, MRM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

3

1. MRM Profitability Analysis

1.1 Basic Checks

  • In the past year MRM was profitable.
  • MRM had a negative operating cash flow in the past year.
  • In multiple years MRM reported negative net income over the last 5 years.
  • In the past 5 years MRM always reported negative operating cash flow.
MRM Yearly Net Income VS EBIT VS OCF VS FCFMRM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B

1.2 Ratios

  • MRM has a Return On Assets of 0.51%. This is comparable to the rest of the industry: MRM outperforms 50.00% of its industry peers.
  • MRM has a Return On Equity of 16.67%. This is in the better half of the industry: MRM outperforms 79.73% of its industry peers.
Industry RankSector Rank
ROA 0.51%
ROE 16.67%
ROIC N/A
ROA(3y)1.91%
ROA(5y)-4.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MRM Yearly ROA, ROE, ROICMRM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

  • MRM's Profit Margin of 0.50% is in line compared to the rest of the industry. MRM outperforms 51.35% of its industry peers.
  • MRM's Profit Margin has improved in the last couple of years.
  • MRM's Operating Margin has declined in the last couple of years.
  • MRM has a worse Gross Margin (25.05%) than 71.62% of its industry peers.
  • MRM's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 0.5%
GM 25.05%
OM growth 3YN/A
OM growth 5Y-50.92%
PM growth 3YN/A
PM growth 5Y32.28%
GM growth 3Y1.14%
GM growth 5Y2.16%
MRM Yearly Profit, Operating, Gross MarginsMRM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. MRM Health Analysis

2.1 Basic Checks

  • MRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MRM has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, MRM has more shares outstanding
  • The debt/assets ratio for MRM is higher compared to a year ago.
MRM Yearly Shares OutstandingMRM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
MRM Yearly Total Debt VS Total AssetsMRM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

  • Based on the Altman-Z score of 0.41, we must say that MRM is in the distress zone and has some risk of bankruptcy.
  • MRM has a Altman-Z score (0.41) which is in line with its industry peers.
  • A Debt/Equity ratio of 5.53 is on the high side and indicates that MRM has dependencies on debt financing.
  • With a Debt to Equity ratio value of 5.53, MRM is not doing good in the industry: 81.08% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 5.53
Debt/FCF N/A
Altman-Z 0.41
ROIC/WACCN/A
WACC2.26%
MRM Yearly LT Debt VS Equity VS FCFMRM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 1B -1B

2.3 Liquidity

  • A Current Ratio of 0.24 indicates that MRM may have some problems paying its short term obligations.
  • The Current ratio of MRM (0.24) is worse than 89.19% of its industry peers.
  • MRM has a Quick Ratio of 0.24. This is a bad value and indicates that MRM is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.21, MRM is doing worse than 89.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.24
Quick Ratio 0.21
MRM Yearly Current Assets VS Current LiabilitesMRM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MRM Growth Analysis

3.1 Past

  • MRM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 162.73%, which is quite impressive.
  • Measured over the past years, MRM shows a very strong growth in Earnings Per Share. The EPS has been growing by 47.92% on average per year.
  • MRM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.26%.
  • MRM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.25% yearly.
EPS 1Y (TTM)162.73%
EPS 3YN/A
EPS 5Y47.92%
EPS Q2Q%26.3%
Revenue 1Y (TTM)14.26%
Revenue growth 3Y15.33%
Revenue growth 5Y16.25%
Sales Q2Q%-6.67%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MRM Yearly Revenue VS EstimatesMRM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

More info and screens

Find the best growth stocksShow best growing peers

2

4. MRM Valuation Analysis

4.1 Price/Earnings Ratio

  • MRM is valuated reasonably with a Price/Earnings ratio of 10.00.
  • Based on the Price/Earnings ratio, MRM is valued cheaper than 81.08% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of MRM to the average of the S&P500 Index (26.46), we can say MRM is valued rather cheaply.
Industry RankSector Rank
PE 10
Fwd PE N/A
MRM Price Earnings VS Forward Price EarningsMRM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • MRM's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 19.75
MRM Per share dataMRM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)0.21
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MRM Dividend Analysis

5.1 Amount

  • MRM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MRM Fundamentals: All Metrics, Ratios and Statistics

MEDIROM HEALTHCARE TECHNOLOG

NASDAQ:MRM (3/9/2026, 8:23:28 PM)

Premarket: 1.26 -0.04 (-3.08%)

1.3

0 (0%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)05-20
Earnings (Next)N/A
Inst Owners0.23%
Inst Owner Change-88.79%
Ins Owners25.57%
Ins Owner ChangeN/A
Market Cap10.27M
Revenue(TTM)8.07B
Net Income(TTM)40.47M
Analysts0
Price TargetN/A
Short Float %0.48%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 10
Fwd PE N/A
P/S 0.2
P/FCF N/A
P/OCF N/A
P/B 6.71
P/tB N/A
EV/EBITDA 19.75
EPS(TTM)0.13
EY10%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS6.44
BVpS0.19
TBVpS-2.36
PEG (NY)N/A
PEG (5Y)0.21
Graham Number0.75
Profitability
Industry RankSector Rank
ROA 0.51%
ROE 16.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 0.5%
GM 25.05%
FCFM N/A
ROA(3y)1.91%
ROA(5y)-4.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-50.92%
PM growth 3YN/A
PM growth 5Y32.28%
GM growth 3Y1.14%
GM growth 5Y2.16%
F-Score4
Asset Turnover1.01
Health
Industry RankSector Rank
Debt/Equity 5.53
Debt/FCF N/A
Debt/EBITDA 9
Cap/Depr 182.82%
Cap/Sales 7.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.24
Quick Ratio 0.21
Altman-Z 0.41
F-Score4
WACC2.26%
ROIC/WACCN/A
Cap/Depr(3y)216.74%
Cap/Depr(5y)157.89%
Cap/Sales(3y)7.57%
Cap/Sales(5y)5.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.73%
EPS 3YN/A
EPS 5Y47.92%
EPS Q2Q%26.3%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)14.26%
Revenue growth 3Y15.33%
Revenue growth 5Y16.25%
Sales Q2Q%-6.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y72.6%
EBIT growth 3YN/A
EBIT growth 5Y-42.95%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-22.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-110.8%
OCF growth 3YN/A
OCF growth 5YN/A

MEDIROM HEALTHCARE TECHNOLOG / MRM FAQ

What is the ChartMill fundamental rating of MEDIROM HEALTHCARE TECHNOLOG (MRM) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MRM.


What is the valuation status of MEDIROM HEALTHCARE TECHNOLOG (MRM) stock?

ChartMill assigns a valuation rating of 2 / 10 to MEDIROM HEALTHCARE TECHNOLOG (MRM). This can be considered as Overvalued.


How profitable is MEDIROM HEALTHCARE TECHNOLOG (MRM) stock?

MEDIROM HEALTHCARE TECHNOLOG (MRM) has a profitability rating of 3 / 10.


Can you provide the PE and PB ratios for MRM stock?

The Price/Earnings (PE) ratio for MEDIROM HEALTHCARE TECHNOLOG (MRM) is 10 and the Price/Book (PB) ratio is 6.71.